AVIVA Semi-Finals: National ME/FM Action Network is competing for $100,000
The National ME/FM Action Network in Canada is competing for $100,000 for biomedical research of ME and FM in the Aviva Community Fund contest. With thanks to all who helped, they made it through the first round of voting into the Semi-Finals.
Discuss the article on the Forums.

Rituximab for Hep C not responding to antivirals - relapse risk remains

Discussion in 'Other Health News and Research' started by natasa778, Jan 31, 2014.

  1. natasa778

    natasa778 Senior Member

    Messages:
    1,592
    Likes:
    1,623
    London UK
    Small scale trial but very encouraging and interesting results

    A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.


     
    Bob likes this.
  2. natasa778

    natasa778 Senior Member

    Messages:
    1,592
    Likes:
    1,623
    London UK
    Should have mentioned FATIGUE being present in 2/3 of Hep C patients, amongst other clinical presentations. Would be interesting to know if that changes after Rituximab treatment ...

    Cryoglobulin production present in over a third.
     

See more popular forum discussions.

Share This Page